InvestorsHub Logo
Followers 6
Posts 1072
Boards Moderated 0
Alias Born 04/09/2007

Re: None

Friday, 11/13/2020 11:47:47 AM

Friday, November 13, 2020 11:47:47 AM

Post# of 1086
sounds promising.."With the initiation of the Phase 3 ORCA-2 trial and the breakthrough evidence, both mechanistically and clinically, in support of cytisinicline in comparison to Chantix, the third quarter of 2020 has undeniably been the most pivotal in the history of our company," commented John Bencich, Chief Executive Officer of Achieve.
Q3 results


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ACHV News